<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085730</url>
  </required_header>
  <id_info>
    <org_study_id>STU 2021-0916</org_study_id>
    <nct_id>NCT05085730</nct_id>
  </id_info>
  <brief_title>Assessment Skin Quality and Efficacy of Dermal Line After Four Bipolar Radiofrequency Microneedling Treatments</brief_title>
  <official_title>Clinical Assessment of Skin Quality and Efficacy of Dermal Line Improvement Following Four Bipolar Radiofrequency Microneedling Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to evaluate the safety and effectiveness of the InMode Morpheus8 System to&#xD;
      treat facial and neck skin and assess its effect on skin quality and dermal lines. This&#xD;
      device has been FDA cleared for full body subdermal adipose tissue remodeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and efficacy of a bipolar&#xD;
      fractional radiofrequency treatment via use of the InMode Morpheus8 System to achieve skin&#xD;
      texture and quality change and to treat facial fine lines and wrinkles of the lower face.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of fine lines and wrinkles</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>Lemperle Wrinkle Assessment Scale- wrinkling will be assessed according to scales definitions.&#xD;
0- No wrinkles&#xD;
Just perceptible wrinkles&#xD;
Shallow wrinkles&#xD;
Moderately thick wrinkles&#xD;
Deep wrinkles, well defined edges&#xD;
Very deep wrinkles, redundant folds&#xD;
Lower value would indicate improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of fine lines</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>Allergan Scale for Fine Lines- fine lines of the midface/cheeks will be assessed according to the scales definition.&#xD;
0- None&#xD;
Minimal (1-2 superficial lines)&#xD;
Moderate (3-5 superficial lines)&#xD;
Severe (&lt;5 superficial lines; no crosshatching)&#xD;
Diffuse (diffuse superficial lines; crosshatching)&#xD;
Lower value would indicate improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of skin roughness</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>Allergan Skin Roughness Scale Assessment- roughness will be assessed according to the scaled definitions based on skin coarseness, crosshatching and elastosis in midface area.&#xD;
0- None (smooth visual skin texture)&#xD;
Minimal (slightly course and uneven visual skin texture)&#xD;
Moderate (Moderately coarse and uneven visual skin texture; early elastosis)&#xD;
Severe (severe coarse visual skin texture, crosshatching lines; some elastosis)&#xD;
Diffuse (extreme coarse visual skin texture, deep crosshatched creases; extreme elastosis)&#xD;
Lower value would indicate improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician's Global Aesthetic Improvement Scale (CGAIS)</measure>
    <time_frame>3 Months and 6 Months</time_frame>
    <description>Scale will be used to assess aesthetic change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline, Day 30, Day 60, Day 90, Month 3 and Month 6</time_frame>
    <description>Adverse events will be monitored at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Aesthetic Improvement Scale (SGAIS)</measure>
    <time_frame>3 Months and 6 Months</time_frame>
    <description>Scale will be used to assess aesthetic change&#xD;
Very much improved&#xD;
Much improved&#xD;
Improved&#xD;
No Change&#xD;
Worse&#xD;
Lower value would indicate improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Questionnaire</measure>
    <time_frame>3 Months and 6 Months</time_frame>
    <description>Patients will be asked to complete a subjective assessment comprising of 3 questions-&#xD;
improvement on fine lines and wrinkles&#xD;
satisfaction with the treatment&#xD;
treatment recommendation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exploratory skin measurements- high resolution ultrasound</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>high resolution ultrasound will be utilized to assess skin thickness/density.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exploratory skin measurements- OCT</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>OCT will be used to gather topographical and histologic images of treated skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exploratory skin measurements- TEWL</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>TEWL measurements (Bio Aquaflux) will be used to evaluate barrier function of the skin epidermal layer to determine healing after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exploratory skin measurements- BTC</measure>
    <time_frame>Baseline, 3 Months and 6 Months</time_frame>
    <description>BCT 2000 to assess skin thickness, density, firmness as well as the integrity of the stratum corneum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in micro-biopsy collection- Gene Expression</measure>
    <time_frame>Baseline, 3 Month and 6 Months</time_frame>
    <description>Gene expression assessments will be completed tp analyze protein related to collagen, elastin, and the extracellular matrix production.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in micro-biopsy collection- Histology</measure>
    <time_frame>Baseline, 3 Month and 6 Months</time_frame>
    <description>Histological assessments will be completed to correlate changes to the skin after treatments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 4 separate treatments with the InMode Morpheus8 System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InMode Morpheus8 System</intervention_name>
    <description>The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female adults between ages 21-70 years of age.&#xD;
&#xD;
          2. Presence of facial dermal lines and skin changes of the lower face associated with age&#xD;
             or environmental exposure.&#xD;
&#xD;
          3. Confirmed BMI â‰¤ 35.&#xD;
&#xD;
          4. Subjects who can read, understand, and sign the Informed Consent Form.&#xD;
&#xD;
          5. Subjects willing and able to comply with all study requirements.&#xD;
&#xD;
          6. Fitzpatrick skin type I-VI.&#xD;
&#xD;
          7. Minimum of 1 on the Lemperle Wrinkle Assessment Scale, Allergan Fine Line Scale and&#xD;
             Allergan Skin Roughness Scale&#xD;
&#xD;
          8. Subject is willing not to undergo any type of aesthetic procedure that could confound&#xD;
             the study device treatment effects until he/she completes the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active localized or systemic infections, that may alter wound healing.&#xD;
&#xD;
          2. Immunocompromised subjects.&#xD;
&#xD;
          3. Subjects with coagulation disorder.&#xD;
&#xD;
          4. History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g.,&#xD;
             tetracycline or sulfa drugs).&#xD;
&#xD;
          5. Pregnant and/or lactating (All female volunteers will be advised about using birth&#xD;
             control during the period of study).&#xD;
&#xD;
          6. 5 on the Lemperle Wrinkle Assessment Scale or 4 on the Allergan Fine Line Scale and/or&#xD;
             Allergan Skin Roughness Scales&#xD;
&#xD;
          7. Scarring in areas to be treated.&#xD;
&#xD;
          8. Tattoos in the treatment areas to be treated.&#xD;
&#xD;
          9. Significant open facial wounds or lesions.&#xD;
&#xD;
         10. Severe or cystic acne in treatment areas.&#xD;
&#xD;
         11. Current active smoker.&#xD;
&#xD;
         12. Use of Accutane (Isotretinoin) within the past 6 months.&#xD;
&#xD;
         13. Use of topical retinoids within 48 hours.&#xD;
&#xD;
         14. Use of prescription anticoagulants.&#xD;
&#xD;
         15. Pacemaker or internal defibrillator.&#xD;
&#xD;
         16. History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme&#xD;
             dry and fragile skin).&#xD;
&#xD;
         17. Subjects on current oral corticosteroid therapy or within the past 6 months&#xD;
&#xD;
         18. Metal implants in the treatment area.&#xD;
&#xD;
         19. In the opinion of the investigator, subject is unwilling or unable to adhere to all&#xD;
             study requirements, including application and follow-up visits.&#xD;
&#xD;
         20. Subjects with a history of radiation therapy to the treatment area.&#xD;
&#xD;
         21. Subject has a history of allergy to lidocaine or ester-based local anesthetics.&#xD;
&#xD;
         22. Subjects with significant cardiac history or rhythm disturbance who may be unable to&#xD;
             tolerate lidocaine with epinephrine.&#xD;
&#xD;
         23. Subjects with any skin pathology or condition in the treatment area that could&#xD;
             interfere with evaluation or with the use of typical ancillary medical treatments or&#xD;
             care used before, during or after treatments (e.g. psoriasis, rosacea, eczema,&#xD;
             seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as&#xD;
             post inflammatory hyperpigmentation).&#xD;
&#xD;
         24. Subjects who are unwilling to shave excessive hair in the treatment area that might&#xD;
             influence or impair evaluation in the opinion of the Investigator.&#xD;
&#xD;
         25. Subjects have undergone skin resurfacing or tightening treatments in the treatment&#xD;
             area over the past year.&#xD;
&#xD;
         26. Subjects have undergone dermatological treatments such as fillers and neurotoxins for&#xD;
             the past 6 months in the treatment area.&#xD;
&#xD;
         27. Subjects have undergone laser and light treatments in the treatment area over the past&#xD;
             3 months.&#xD;
&#xD;
         28. Subjects have undergone superficial peel or microdermabrasion within 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Kenkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern- Department of Plastic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Barillas</last_name>
    <phone>214-645-8907</phone>
    <email>jennifer.barillas@utsouthwestern.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Jeffrey M. Kenkel</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>skin aging</keyword>
  <keyword>bipolar radiofrequency</keyword>
  <keyword>microneedling</keyword>
  <keyword>dermal lines</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

